Matches in SemOpenAlex for { <https://semopenalex.org/work/W3123629693> ?p ?o ?g. }
- W3123629693 endingPage "337" @default.
- W3123629693 startingPage "325" @default.
- W3123629693 abstract "ABSTRACTIntroduction: The current SARS-CoV-2 pandemic urgently demands for both prevention and treatment strategies. RNA-dependent RNA-polymerase (RdRp), which has no counterpart in human cells, is an excellent target for drug development. Given the time-consuming process of drug development, repurposing drugs approved for other indications or at least successfully tested in terms of safety and tolerability, is an attractive strategy to rapidly provide an effective medication for severe COVID-19 cases.Areas covered: The currently available data and upcominSg studies on RdRp which can be repurposed to halt SARS-CoV-2 replication, are reviewed.Expert opinion: Drug repurposing and design of novel compounds are proceeding in parallel to provide a quick response and new specific drugs, respectively. Notably, the proofreading SARS-CoV-2 exonuclease activity could limit the potential for drugs designed as immediate chain terminators and favor the development of compounds acting through delayed termination. While vaccination is awaited to curb the SARS-CoV-2 epidemic, even partially effective drugs from repurposing strategies can be of help to treat severe cases of disease. Considering the high conservation of RdRp among coronaviruses, an improved knowledge of its activity in vitro can provide useful information for drug development or drug repurposing to combat SARS-CoV-2 as well as future pandemics.KEYWORDS: COVID-19drug repurposingnucleoside inhibitorsrna polymerasesars-CoV-2 Article highlights• RNA‐dependent RNA polymerase (RdRp) plays an essential role in SARS‐CoV‐2 viral replication.• RdRp motifs are highly conserved among coronaviruses and RNA positive-stranded viruses, offering an attractive target for broad-spectrum antivirals• This review focuses on most promising repurposed drugs inhibiting the SARS-COV-2 RdRp• For each drug, in vitro and in vivo data against SARS-COV-2 are summarized• The review provides an expert opinion of the clinical use of nucleoside analogs in COVID-19 treatmentThis box summarizes key points contained in the article.Declaration of interestM Zazzi has received grants and personal fees from Gilead Sciences, Janssen-Cilag, Merck Sharp and Dohme, ViiV Healthcare, outside the current work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis work was partially supported by funds from Ministero dell'Istruzione, dell'Università e della Ricerca, project PRIN 2017, ORIGINALE CHEMIAE in Antiviral Strategy - Origin and Modernization of Multi-Component Chemistry as a Source of Innovative Broad-Spectrum Antiviral Strategy (cod. 2017BMK8JR)." @default.
- W3123629693 created "2021-02-01" @default.
- W3123629693 creator A5002487044 @default.
- W3123629693 creator A5032859619 @default.
- W3123629693 creator A5091290072 @default.
- W3123629693 date "2021-03-03" @default.
- W3123629693 modified "2023-10-02" @default.
- W3123629693 title "SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19" @default.
- W3123629693 cites W1515293536 @default.
- W3123629693 cites W1582561043 @default.
- W3123629693 cites W1966199377 @default.
- W3123629693 cites W1971292277 @default.
- W3123629693 cites W1974756544 @default.
- W3123629693 cites W1982301628 @default.
- W3123629693 cites W1984259198 @default.
- W3123629693 cites W1993145638 @default.
- W3123629693 cites W1997713382 @default.
- W3123629693 cites W2004837257 @default.
- W3123629693 cites W2005094081 @default.
- W3123629693 cites W2009987166 @default.
- W3123629693 cites W2029628478 @default.
- W3123629693 cites W2030429617 @default.
- W3123629693 cites W2034462612 @default.
- W3123629693 cites W2039441730 @default.
- W3123629693 cites W2040845886 @default.
- W3123629693 cites W2041802815 @default.
- W3123629693 cites W2043685036 @default.
- W3123629693 cites W2044088857 @default.
- W3123629693 cites W2044453886 @default.
- W3123629693 cites W2058203122 @default.
- W3123629693 cites W2072202424 @default.
- W3123629693 cites W2075351796 @default.
- W3123629693 cites W2089539469 @default.
- W3123629693 cites W2092052419 @default.
- W3123629693 cites W2097886963 @default.
- W3123629693 cites W2151338378 @default.
- W3123629693 cites W2167623612 @default.
- W3123629693 cites W2189487392 @default.
- W3123629693 cites W2256993288 @default.
- W3123629693 cites W2292021561 @default.
- W3123629693 cites W2337422248 @default.
- W3123629693 cites W2344135905 @default.
- W3123629693 cites W2346961068 @default.
- W3123629693 cites W2410066853 @default.
- W3123629693 cites W2526191593 @default.
- W3123629693 cites W2530519158 @default.
- W3123629693 cites W2550848359 @default.
- W3123629693 cites W2557042960 @default.
- W3123629693 cites W2581273760 @default.
- W3123629693 cites W2582590404 @default.
- W3123629693 cites W2593309919 @default.
- W3123629693 cites W2725497285 @default.
- W3123629693 cites W2736549761 @default.
- W3123629693 cites W2739679816 @default.
- W3123629693 cites W2754416383 @default.
- W3123629693 cites W2756207857 @default.
- W3123629693 cites W2761517030 @default.
- W3123629693 cites W2770157223 @default.
- W3123629693 cites W2777914188 @default.
- W3123629693 cites W2782897656 @default.
- W3123629693 cites W2793022939 @default.
- W3123629693 cites W2797336458 @default.
- W3123629693 cites W2803931793 @default.
- W3123629693 cites W2807193652 @default.
- W3123629693 cites W2896002881 @default.
- W3123629693 cites W2896485495 @default.
- W3123629693 cites W2914796231 @default.
- W3123629693 cites W2935101654 @default.
- W3123629693 cites W2952023305 @default.
- W3123629693 cites W2953224333 @default.
- W3123629693 cites W2954672408 @default.
- W3123629693 cites W2972279236 @default.
- W3123629693 cites W2976199806 @default.
- W3123629693 cites W2979108578 @default.
- W3123629693 cites W2981723136 @default.
- W3123629693 cites W2989362072 @default.
- W3123629693 cites W2991491848 @default.
- W3123629693 cites W2998883241 @default.
- W3123629693 cites W2999497689 @default.
- W3123629693 cites W3000413850 @default.
- W3123629693 cites W3001456238 @default.
- W3123629693 cites W3005212621 @default.
- W3123629693 cites W3006564542 @default.
- W3123629693 cites W3007227604 @default.
- W3123629693 cites W3007969569 @default.
- W3123629693 cites W3008668537 @default.
- W3123629693 cites W3012455685 @default.
- W3123629693 cites W3012588029 @default.
- W3123629693 cites W3013369257 @default.
- W3123629693 cites W3014203610 @default.
- W3123629693 cites W3014708904 @default.
- W3123629693 cites W3015429854 @default.
- W3123629693 cites W3015472194 @default.
- W3123629693 cites W3015490759 @default.
- W3123629693 cites W3015554176 @default.
- W3123629693 cites W3018023298 @default.
- W3123629693 cites W3020358199 @default.
- W3123629693 cites W3022722383 @default.